Can a Patient Stop HRT Abruptly?
Yes, a patient can stop HRT abruptly—there is no medical necessity to taper, and studies show no significant difference in outcomes between abrupt discontinuation and gradual tapering. 1
The Evidence on Discontinuation Methods
The Endocrine Society's 2015 clinical practice guideline explicitly addresses this question with a clear recommendation: for women preparing to discontinue MHT, a shared decision-making approach should be used to elicit individual preference about adopting a gradual taper versus abrupt discontinuation. 1 This recommendation is based on evidence showing that multiple studies comparing taper protocols versus abrupt cessation detected no differences in outcomes. 1
What the Research Shows
The clinical trial data consistently demonstrates:
No clinically meaningful difference exists between methods: Four RCTs directly compared tapered versus abrupt discontinuation. Two found that abrupt discontinuers initially experienced greater symptoms, but after completion of the tapered withdrawal period, symptoms were comparable between groups. Two other RCTs found no difference at all. 2
Tapering only delays symptom recurrence: A 2006 randomized trial found that gradual discontinuation merely postponed vasomotor symptoms rather than preventing them. By 6 months, the gradual taper group actually had worse vasomotor symptoms than the abrupt cessation group, and by 9-12 months there was no difference. 3
Another trial confirmed this finding: A 2010 Brazilian study showed that reducing estrogen doses for 2 or 4 months before stopping did not differ from abrupt cessation regarding vasomotor symptoms. 4
What Actually Happens When HRT is Stopped
Regardless of method, patients should expect:
Symptom recurrence is common: Menopausal symptoms and joint pain frequently recur when MHT is discontinued. 1 The most common symptoms are unspecified menopausal symptoms (84.4%), sleep disturbances (51.9%), and vasomotor symptoms (45.4%). 2
Many women restart therapy: Approximately 20.7% of women restart HRT, with vasomotor symptoms being the most commonly cited reason. 2
Most women successfully discontinue: About 75% of women who try to stop are able to discontinue HRT without major difficulty. 5
Clinical Approach to Discontinuation
The method of discontinuation should be based entirely on patient preference, as there is no evidence-based advantage to either approach. 1
For patients who prefer abrupt discontinuation:
- This is medically safe and appropriate
- Symptoms may appear immediately but will not be worse long-term than with tapering
- Prepare patients that symptoms may occur and discuss management options
For patients who prefer gradual tapering:
- This is also acceptable if it provides psychological comfort
- Understand that it delays rather than prevents symptom recurrence
- Some women find that very low-dose estrogen maintains adequate symptom relief and prefer this to complete discontinuation 1
Important Caveats
The decision to discontinue should be revisited at least annually, targeting the shortest total duration consistent with treatment goals and evolving risk assessment. 1 However, once the decision to stop is made, the method itself does not impact outcomes.
For women with persistent symptoms after discontinuation, options include:
- Restarting HRT at a lower dose
- Using nonhormonal therapies (SSRIs/SNRIs, gabapentin, pregabalin, or clonidine) 1
- Lifestyle modifications for mild symptoms 1
Special consideration for young women with premature ovarian insufficiency or early menopause: These women should continue MHT until the anticipated age of natural menopause before considering discontinuation. 1
The bottom line: abrupt discontinuation is safe and evidence-based—tapering offers no proven benefit in preventing or minimizing symptom recurrence, though either approach is acceptable based on patient preference.